N
3.80
0.04 (1.06%)
| Previous Close | 3.76 |
| Open | 3.78 |
| Volume | 199,067 |
| Avg. Volume (3M) | 1,261,270 |
| Market Cap | 162,637,312 |
| Price / Earnings (Forward) | 34.25 |
| Price / Sales | 43.83 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2026 |
| Diluted EPS (TTM) | -1.96 |
| Current Ratio (MRQ) | 0.220 |
| Operating Cash Flow (TTM) | -10.45 M |
| Levered Free Cash Flow (TTM) | 3.23 M |
| Return on Assets (TTM) | -191.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NRX Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.13 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.88% |
| % Held by Institutions | 13.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bleakley Financial Group, Llc | 31 Mar 2026 | 117,204 |
| Headlands Technologies Llc | 31 Mar 2026 | 39,394 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |